曲美他嗪联合三磷酸腺苷在冠心病伴心功能不全治疗中的应用效果

目的 研究曲美他嗪联合三磷酸腺苷在冠心病伴心功能不全治疗中的应用效果.方法 110例冠心病伴心功能不全患者,以就诊单双号分为常规组和联合组,各55例.常规组采用曲美他嗪治疗,联合组采用曲美他嗪联合三磷酸腺苷治疗.对比两组患者治疗前后的心功能指标,死亡情况,不良反应发生情况.结果 治疗后,两组患者的左室射血分数、每分输出...

Application effect of trimetazidine combined with adenosine triphosphate in the treatment of coronary heart disease with cardiac insufficiency

Objective To study the application effect of trimetazidine combined with adenosine triphosphate in the treatment of cardiac insufficiency with coronary heart disease.Methods A total of 110 patients with coronary heart disease and cardiac insufficiency were divided into conventional group and combination group,with 55 cases in each group.The conventional group was treated with trimetazidine,and the combination group was treated with trimetazidine and adenosine triphosphate.The cardiac function indexes before and after treatment,mortality,and occurrence of adverse reactions were compared between the two groups.Results After treatment,the left ventricular ejection fraction and cardiac output of the two groups were higher than those of this group before treatment,and the left ventricular end-systolic diameter and left ventricular end-diastolic diameter were less than those of this group before treatment;the left ventricular ejection fraction(57.92±1.25)%and cardiac output(5.49±0.62)L/min of the combination group were higher than(42.66±1.41)%and(3.97±0.39)L/min of the conventional group,and the left ventricular end-systolic diameter(45.33±2.19)mm and left ventricular end-diastolic diameter(48.34±3.30)mm were less than(59.68±2.45)and(63.21±2.98)mm of the conventional group;all differences were statistically significant(P<0.05).At 12 months of follow-up,the mortality rate 3.64%in the combination group was lower than 14.55%in the conventional group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of trimetazidine and adenosine triphosphate for the treatment of patients with coronary heart disease and cardiac insufficiency can effectively improve the patient's cardiac function and prolong the patient's prognostic survival time,and the combination of the two drugs does not aggravate the adverse drug reactions of the patients.It has high drug safety and high clinical application value.